Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Treasury Shares (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Treasury Shares for 4 consecutive years, with $19.0 as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares changed 0.0% to $19.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $19.0, a 0.0% change, with the full-year FY2025 number at $19.0, changed 0.0% from a year prior.
  • Treasury Shares was $19.0 for Q4 2025 at Phathom Pharmaceuticals, roughly flat from $19.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $699624.0 in Q2 2022 to a low of $19.0 in Q1 2022.
  • A 4-year average of $91447.6 and a median of $19.0 in 2022 define the central range for Treasury Shares.
  • Biggest YoY gain for Treasury Shares was 167500.0% in 2023; the steepest drop was 100.0% in 2023.
  • Phathom Pharmaceuticals' Treasury Shares stood at $254437.0 in 2022, then tumbled by 99.99% to $19.0 in 2023, then changed by 0.0% to $19.0 in 2024, then changed by 0.0% to $19.0 in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Treasury Shares are $19.0 (Q4 2025), $19.0 (Q3 2025), and $19.0 (Q2 2025).